An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis

Clinical Infectious Diseases

Volumn 27, Issue 6, 1998, Pages 1406-1412

  Ellis, M ^a   Spence, D ^b   De Pauw, B ^b   Meunier, F ^b   Marinus, A ^b   Collette, L ^b   Sylvester, R ^b   Meis, J ^b   Boogaerts, M ^b   Selleslag, D ^b   Krcmery, V ^b   Von Sinner, W ^b   MacDonald, P ^b   Doyen, C ^b   Vandercam, B ^b  

^a TAWAM HOSPITAL   (United Arab Emirates)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032459632     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515033     Document Type: Article

References (15)

1. Pannuti CS, Gingrich RD, Pfaller MA, Wenzel RP. Nosocomial pneumonia in adult patients undergoing bone marrow transplantation: a 9 year study. J Clin Oncol 1991; 9:77-84.
2. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer 1984; 53:411-9.
3. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147-200.
4. De Bock R. Epidemiology of invasive fungal infections in bone marrow transplantation. Bone Marrow Transplant 1994; 14(suppl 5):S1-2.
5. McWhinney PHW, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17:397-404.
6. Denning DA. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23:608-15.
7. Patterson TF, Miniter P, Ryan JL, Andriole VT. Effect of immunosuppression and amphotericin B on aspergillus antigenemia in an experimental model. J Infect Dis 1988; 158:415-22.
8. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EF. Favourable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987; 5:1985-93.
9. Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B: safety data from a phase 2/3 clinical trial with AmBisome. J Antimicrob Chemother 1991; 28(suppl B):83-91.
10. Ringden O, Meunier F, Tollemar J, et al. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother 1991; 28(suppl B):73-82.
11. Ng TTC, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155:1093-8.
12. Tollemar J, Ringden O. Lipid formulations of amphotericin B: less toxicity but at what economic cost? Drug Safety 1995; 13:207-18.
13. Prentice HG, Hann IM, Herbrecht R, et al. A randomised comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-8.
14. Guiot HFL, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994; 18:525-32.
15. Ambisome. In: Mehta DK, ed. British national formulary. No. 33. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 1997:265.